Redmile Group LLC cut its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 4.5% in the 1st quarter, HoldingsChannel.com reports. The firm owned 7,732,808 shares of the company’s stock after selling 361,100 shares during the period. Nurix Therapeutics comprises approximately 7.9% of Redmile Group LLC’s portfolio, making the stock its 5th largest holding. Redmile Group LLC owned approximately 0.07% of Nurix Therapeutics worth $119,859,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in NRIX. General Atlantic L.P. bought a new position in Nurix Therapeutics during the 4th quarter worth approximately $92,899,000. Vanguard Group Inc. increased its stake in Nurix Therapeutics by 32.5% in the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock worth $112,862,000 after purchasing an additional 1,460,736 shares during the period. Baker BROS. Advisors LP lifted its position in Nurix Therapeutics by 20.0% in the fourth quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock valued at $88,373,000 after purchasing an additional 776,431 shares during the last quarter. Flax Pond Capital LLC bought a new stake in Nurix Therapeutics in the fourth quarter valued at approximately $1,521,000. Finally, Perceptive Advisors LLC boosted its stake in shares of Nurix Therapeutics by 151.1% during the fourth quarter. Perceptive Advisors LLC now owns 3,555,877 shares of the company’s stock valued at $67,455,000 after purchasing an additional 2,139,728 shares during the period.
Insider Activity
In other news, insider Gwenn Hansen sold 5,394 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $107,880.00. Following the completion of the sale, the insider directly owned 115,005 shares of the company’s stock, valued at approximately $2,300,100. This trade represents a 4.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total transaction of $233,313.00. Following the sale, the chief financial officer directly owned 37,592 shares in the company, valued at $624,027.20. The trade was a 27.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 25,051 shares of company stock valued at $434,466. Corporate insiders own 6.70% of the company’s stock.
Nurix Therapeutics Stock Up 3.1%
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last released its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The company had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. On average, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.82 earnings per share for the current year.
Analyst Ratings Changes
NRIX has been the topic of several recent analyst reports. HC Wainwright raised their target price on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, July 10th. BTIG Research reiterated a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a report on Friday, July 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Friday, July 17th. Royal Bank Of Canada raised their price target on shares of Nurix Therapeutics from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Friday, July 10th. Finally, Needham & Company LLC restated a “buy” rating and issued a $34.00 price objective on shares of Nurix Therapeutics in a research report on Friday, July 10th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.
Check Out Our Latest Research Report on NRIX
Nurix Therapeutics Profile
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company’s pipeline includes multiple programs in various stages of development.
Featured Articles
- Five stocks we like better than Nurix Therapeutics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report).
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
